12-Nov-2026 20:05:26

BHARATROHANGeneral news

BHARATROHAN : ACHIEVES TECHNOLOGY MILESTONE IN HYPERSPECTRAL IMAGING FOR PHARMA QUALITY SCREENING

• Proprietary hyperspectral imaging system non-destructively differentiated genuine tablets from adulterated or substandard samples in controlled proof-of-concept testing • Testing extended to analgesic, macrolide antibiotic and anti-diabetic tablets plus fixed-dose combinations; adulterants included calcium carbonate, starch, talc, microcrystalline cellulose, gypsum and lactose • Results rest on a limited internal sample set and have not been independently validated, peer-reviewed, or assessed by any regulatory or pharmacopoeial authority • Company is in discussions with multiple regulatory and scientific authorities in India's pharmaceutical quality ecosystem; specific nature and status not disclosed • Internal estimates put pharma screening TAM at ~US$0.8-1.8 billion, SAM ~US$80-350 million and 3-year SOM ~US$1.5-8 million, unaudited and unverified • Extends existing precision-agriculture platform into pharmaceutical quality assurance and anti-counterfeiting

Bharatrohan Airborne Innovations Ltd

Open attachment

← Back to feed